PRFX Stock Overview
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PainReform Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.82 |
| 52 Week High | US$26.41 |
| 52 Week Low | US$0.69 |
| Beta | 0.53 |
| 1 Month Change | -53.62% |
| 3 Month Change | -57.24% |
| 1 Year Change | -88.11% |
| 3 Year Change | -96.99% |
| 5 Year Change | n/a |
| Change since IPO | -98.78% |
Recent News & Updates
Shareholder Returns
| PRFX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.3% | 1.1% | 0.7% |
| 1Y | -88.1% | 9.5% | 23.9% |
Return vs Industry: PRFX underperformed the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: PRFX underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| PRFX volatility | |
|---|---|
| PRFX Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRFX's share price has been volatile over the past 3 months.
Volatility Over Time: PRFX's weekly volatility has decreased from 47% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Ilan Hadar | www.painreform.com |
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd. Fundamentals Summary
| PRFX fundamental statistics | |
|---|---|
| Market cap | US$2.28m |
| Earnings (TTM) | -US$9.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs PRFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRFX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.34m |
| Earnings | -US$9.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRFX perform over the long term?
See historical performance and comparison